Table 3.
Least-squares mean change from baseline at 12 and 24 weeks for patient-reported outcomes
| PRO measures | Week 12 LSM (95% CI) |
Week 24 LSM (95% CI) |
||||
|---|---|---|---|---|---|---|
| Placebo (N=228) | Baricitinib 2 mg (N=229) | Baricitinib 4 mg (N=227) | Placebo (N=228) | Baricitinib 2 mg (N=229) | Baricitinib 4 mg (N=227) | |
| Physical function (HAQ-DI) | −0.36 (−0.43 to −0.29) | −0.57*** (−0.64 to −0.50) | −0.56*** (−0.63 to −0.48) | −0.38 (−0.46 to −0.30) | −0.62*** (−0.70 to −0.54) | −0.62*** (−0.70 to −0.54) |
| Patient's Global Assessment of Disease Activity (PtGA) | −16.8 (−20.0 to −13.6) | −25.3*** (−28.5 to −22.2) | −25.8*** (−29.1 to −22.6) | −18.8 (−22.0 to −15.6) | −27.6*** (−30.8 to −24.5) | −29.1*** (−32.4 to −25.9) |
| Patient's Assessment of Pain | −15.6 (−18.9 to −12.3) | −25.4*** (−28.6 to −22.2) | −23.4*** (−26.7 to −20.1) | −19.6 (−22.9 to −16.3) | −27.4*** (−30.6 to −24.2) | −27.9*** (−31.2 to −24.6) |
| EuroQol-5-Dimensions (EQ-5D-5L) | ||||||
| Health State Index Score | ||||||
| UK algorithm | 0.092 (0.066 to 0.119) | 0.165*** (0.139 to 0.191) | 0.162*** (0.135 to 0.189) | 0.091 (0.063 to 0.119) | 0.157*** (0.130 to 0.184) | 0.186*** (0.158 to 0.215) |
| US algorithm | 0.066 (0.048 to 0.085) | 0.117*** (0.099 to 0.135) | 0.112*** (0.093 to 0.131) | 0.062 (0.042 to 0.082) | 0.111*** (0.092 to 0.130) | 0.131*** (0.111 to 0.151) |
| VAS | 4.5 (1.7 to 7.4) | 13.5*** (10.7 to 16.2) | 11.3*** (8.4 to 14.1) | 7.9 (4.7 to 11.1) | 13.9** (10.8 to 17.0) | 11.0 (7.8 to 14.2) |
**p≤0.01, ***p≤0.001 vs placebo.
LSM, least-squares mean; VAS, visual analogue scale.